Latest Earnings Results: Q2 '26
Estimated EPS
$0.01
Reported EPS
$0.00
Surprise
-100%
Estimated Rev
$238.11M
Reported Rev
$263.71M
Surprise
+10.75%
• Reported GAAP EPS of $0.00 • Reported revenue of $263.71M up 45.38% YoY • Caris Life Sciences now expects full year 2026 revenue to be in the range of $1.03 billion to $1.04 billion, representing growth of 27% to 28% compared to full year 2025.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | $0.03 | -- | -- | N/A |
Q2 '26 | $0.01 | $0.00 | -100.00% | MISSED |
Q1 '26 | -$0.02 | $0.00 | 100.00% | BEAT |
Q4 '25 | $0.03 | $0.28 | 723.07% | BEAT |
Q3 '25 | -$0.18 | $0.08 | 145.67% | BEAT |